NIKKEI 225
38,242.58 +63.12 (+0.17%) HANG SENG
19,142.06 +27.00 (+0.14%) CRUDE OIL
79.20 +0.08 (+0.10%) GOLD FUTURES
2,349.00 +6.00 (+0.26%) DOW
39,431.51 -81.29 (-0.21%) Bitcoin GBP
49,840.67 +986.66 (+2.02%)
Celldex Therapeutics, Inc. (TCE2.F)
| Previous close | 37.80 |
| Open | 36.60 |
| Bid | 37.20 x 0 |
| Ask | 37.40 x 0 |
| Day's range | 36.60 - 36.60 |
| 52-week range | 21.20 - 47.80 |
| Volume | |
| Avg. volume | 12 |
| Market cap | 2.412B |
| Beta (5Y monthly) | 1.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.65 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 64.83 |
ZacksWall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
The consensus price target hints at a 67.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Simply Wall St.Celldex Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Celldex Therapeutics ( NASDAQ:CLDX ) First Quarter 2024 Results Key Financial Results Net loss: US$32.8m (loss widened...
GlobeNewswireCelldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 -- Enrollment completed in Phase 2 CIndU study; 12 week data expected 2H 2024 -- Phase 2 PN study initiated; enrollment progressing in Phase 2 EoE study -- Atopic dermatitis selected as next indication; Phase 2 study to initiate by YE 2024 - HAMPTON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeut
